{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:37:24Z","timestamp":1771529844920,"version":"3.50.1"},"reference-count":71,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI","award":["5R01CA206012-04"],"award-info":[{"award-number":["5R01CA206012-04"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,12,15]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tumor endothelial marker 1 (TEM1) is a protein expressed in the tumor-associated endothelium and\/or stroma of various types of cancer. We previously demonstrated that immunization with a plasmid-DNA vaccine targeting TEM1 reduced tumor progression in three murine cancer models. Radiation therapy (RT) is an established cancer modality used in more than 50% of patients with solid tumors. RT can induce tumor-associated vasculature injury, triggering immunogenic cell death and inhibition of the irradiated tumor and distant non-irradiated tumor growth (abscopal effect). Combination treatment of RT with TEM1 immunotherapy may complement and augment established immune checkpoint blockade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mice bearing bilateral subcutaneous CT26 colorectal or TC1 lung tumors were treated with a novel heterologous TEM1-based vaccine, in combination with RT, and anti-programmed death-ligand 1 (PD-L1) antibody or combinations of these therapies, tumor growth of irradiated and abscopal tumors was subsequently assessed. Analysis of tumor blood perfusion was evaluated by CD31 staining and Doppler ultrasound imaging. Immunophenotyping of peripheral and tumor-infiltrating immune cells as well as functional analysis was analyzed by flow cytometry, ELISpot assay and adoptive cell transfer (ACT) experiments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrate that addition of RT to heterologous TEM1 vaccination reduces progression of CT26 and TC1 irradiated and abscopal distant tumors as compared with either single treatment. Mechanistically, RT increased major histocompatibility complex class I molecule (MHCI) expression on endothelial cells and improved immune recognition of the endothelium by anti-TEM1 T cells with subsequent severe vascular damage as measured by reduced microvascular density and tumor blood perfusion. Heterologous TEM1 vaccine and RT combination therapy boosted tumor-associated antigen (TAA) cross-priming (ie, anti-gp70) and augmented programmed cell death protein 1 (PD-1)\/PD-L1 signaling within CT26 tumor. Blocking the PD-1\/PD-L1 axis in combination with dual therapy further increased the antitumor effect and gp70-specific immune responses. ACT experiments show that anti-gp70 T cells are required for the antitumor effects of the combination therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings describe novel cooperative mechanisms between heterologous TEM1 vaccination and RT, highlighting the pivotal role that TAA cross-priming plays for an effective antitumor strategy. Furthermore, we provide rationale for using heterologous TEM1 vaccination and RT as an add-on to immune checkpoint blockade as triple combination therapy into early-phase clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001636","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T12:58:35Z","timestamp":1612875515000},"page":"e001636","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01895491","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3082-1291","authenticated-orcid":false,"given":"Stefano","family":"Pierini","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Perales-Linares","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Uribe-Herranz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Beghi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giglio","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Pustylnikov","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-4556","authenticated-orcid":false,"given":"Francesca","family":"Costabile","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Rafail","sequence":"additional","affiliation":[{"name":"Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Amici","sequence":"additional","affiliation":[{"name":"School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Marche, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G","family":"Facciponte","sequence":"additional","affiliation":[{"name":"Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantinos","family":"Koumenis","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Facciabene","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"2025100301525344000_9.2.e001636.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2025100301525344000_9.2.e001636.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.031"},{"key":"2025100301525344000_9.2.e001636.3","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"2025100301525344000_9.2.e001636.4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"2025100301525344000_9.2.e001636.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"2025100301525344000_9.2.e001636.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1082504"},{"key":"2025100301525344000_9.2.e001636.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1471"},{"key":"2025100301525344000_9.2.e001636.8","doi-asserted-by":"publisher","DOI":"10.1667\/RR2773.1"},{"key":"2025100301525344000_9.2.e001636.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-012-9329-2"},{"key":"2025100301525344000_9.2.e001636.10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"2025100301525344000_9.2.e001636.11","doi-asserted-by":"crossref","unstructured":"Pierini S , Tanyi JL , Simpkins F . Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight 2020:5.","DOI":"10.1172\/jci.insight.136773"},{"key":"2025100301525344000_9.2.e001636.12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-015-1747-8","article-title":"Targeting tumor vasculature: expanding the potential of DNA cancer vaccines","volume":"64","author":"Ugel","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2025100301525344000_9.2.e001636.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67382"},{"key":"2025100301525344000_9.2.e001636.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2326"},{"key":"2025100301525344000_9.2.e001636.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.3.1558"},{"key":"2025100301525344000_9.2.e001636.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404896101"},{"key":"2025100301525344000_9.2.e001636.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1398878","article-title":"Trial Watch: DNA-based vaccines for oncological indications","volume":"6","author":"Pierini","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100301525344000_9.2.e001636.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500281"},{"key":"2025100301525344000_9.2.e001636.19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000928"},{"key":"2025100301525344000_9.2.e001636.20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21188"},{"key":"2025100301525344000_9.2.e001636.21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CJI.0b013e3181e032c6","article-title":"Heterologous prime\/boost immunization with p53-based vaccines combined with Toll-like receptor stimulation enhances tumor regression","volume":"33","author":"Ishizaki","year":"2010","journal-title":"J Immunother"},{"key":"2025100301525344000_9.2.e001636.22","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.81"},{"key":"2025100301525344000_9.2.e001636.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm881"},{"key":"2025100301525344000_9.2.e001636.24","doi-asserted-by":"publisher","DOI":"10.3390\/v2020435"},{"key":"2025100301525344000_9.2.e001636.25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01926-14"},{"key":"2025100301525344000_9.2.e001636.26","doi-asserted-by":"crossref","first-page":"15031","DOI":"10.1038\/mtm.2015.31","article-title":"A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer","volume":"2","author":"Kim","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100301525344000_9.2.e001636.27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20569"},{"key":"2025100301525344000_9.2.e001636.28","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.vaccine.2016.04.045","article-title":"Muc1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model","volume":"34","author":"Zhang","year":"2016","journal-title":"Vaccine"},{"key":"2025100301525344000_9.2.e001636.29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2018.06.004","article-title":"Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect","volume":"200","author":"Liu","year":"2018","journal-title":"Immunol Lett"},{"key":"2025100301525344000_9.2.e001636.30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jitc-2019-000464","article-title":"NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer","volume":"8","author":"Walker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100301525344000_9.2.e001636.31","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0204-3"},{"key":"2025100301525344000_9.2.e001636.32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1172\/JCI124332","article-title":"Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response","volume":"130","author":"Uribe-Herranz","year":"2020","journal-title":"J Clin Invest"},{"key":"2025100301525344000_9.2.e001636.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.09.001"},{"key":"2025100301525344000_9.2.e001636.34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jnci\/djw261","article-title":"Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2025100301525344000_9.2.e001636.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9730"},{"key":"2025100301525344000_9.2.e001636.36","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.2000.1691"},{"key":"2025100301525344000_9.2.e001636.37","doi-asserted-by":"crossref","unstructured":"Demaria S , Formenti SC . Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012;2.doi:10.3389\/fonc.2012.00095","DOI":"10.3389\/fonc.2012.00095"},{"key":"2025100301525344000_9.2.e001636.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.041"},{"key":"2025100301525344000_9.2.e001636.39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4048\/jbc.2019.22.e5","article-title":"Tumor-Associated macrophages as potential prognostic biomarkers of invasive breast cancer","volume":"22","author":"Jeong","year":"2019","journal-title":"J Breast Cancer"},{"key":"2025100301525344000_9.2.e001636.40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138581","article-title":"Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer","volume":"5","author":"Ugolini","year":"2020","journal-title":"JCI Insight"},{"key":"2025100301525344000_9.2.e001636.41","doi-asserted-by":"crossref","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"2025100301525344000_9.2.e001636.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519623112"},{"key":"2025100301525344000_9.2.e001636.43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94952","article-title":"Gut microbiota modulates adoptive cell therapy via CD8\u03b1 dendritic cells and IL-12","volume":"3","author":"Uribe-Herranz","year":"2018","journal-title":"JCI Insight"},{"key":"2025100301525344000_9.2.e001636.44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502672"},{"key":"2025100301525344000_9.2.e001636.45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/gt.2008.81","article-title":"Immunogenicity and safety profiles of genetic vaccines against human HER-2\/neu in cynomolgus monkeys","volume":"15","author":"H-J","year":"2008","journal-title":"Gene Ther"},{"key":"2025100301525344000_9.2.e001636.46","doi-asserted-by":"publisher","DOI":"10.1089\/10430340050015581"},{"key":"2025100301525344000_9.2.e001636.47","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5415.808"},{"key":"2025100301525344000_9.2.e001636.48","doi-asserted-by":"publisher","DOI":"10.1038\/80506"},{"key":"2025100301525344000_9.2.e001636.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03175.x"},{"key":"2025100301525344000_9.2.e001636.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00208-8"},{"key":"2025100301525344000_9.2.e001636.51","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/iub.2019","article-title":"T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy","volume":"71","author":"Hajari Taheri","year":"2019","journal-title":"IUBMB Life"},{"key":"2025100301525344000_9.2.e001636.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.018"},{"key":"2025100301525344000_9.2.e001636.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"2025100301525344000_9.2.e001636.54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1919764117"},{"key":"2025100301525344000_9.2.e001636.55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/imr.12568","article-title":"Immune recognition of irradiated cancer cells","volume":"280","author":"Wennerberg","year":"2017","journal-title":"Immunol Rev"},{"key":"2025100301525344000_9.2.e001636.56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0115"},{"key":"2025100301525344000_9.2.e001636.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"2025100301525344000_9.2.e001636.58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"2025100301525344000_9.2.e001636.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870"},{"key":"2025100301525344000_9.2.e001636.60","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"2025100301525344000_9.2.e001636.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"2025100301525344000_9.2.e001636.62","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41416-018-0281-9","article-title":"A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours","volume":"119","author":"Maity","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100301525344000_9.2.e001636.63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597"},{"key":"2025100301525344000_9.2.e001636.64","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100301525344000_9.2.e001636.65","first-page":"5999","article-title":"On OX40 and PD-1 combination: why should OX40 be first in sequence? clin cancer Res","volume":"23","author":"Colombo","year":"2017","journal-title":"American Association for Cancer Research"},{"key":"2025100301525344000_9.2.e001636.66","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0292"},{"key":"2025100301525344000_9.2.e001636.67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29567"},{"key":"2025100301525344000_9.2.e001636.68","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5725-y","article-title":"Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication","volume":"19","author":"Maynard","year":"2019","journal-title":"BMC Cancer"},{"key":"2025100301525344000_9.2.e001636.69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1722043115"},{"key":"2025100301525344000_9.2.e001636.70","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23413"},{"key":"2025100301525344000_9.2.e001636.71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1326442","article-title":"Local endothelial complement activation reverses endothelial quiescence, enabling T-cell homing, and tumor control during T-cell immunotherapy","volume":"6","author":"Facciabene","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:53:00Z","timestamp":1759481580000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,9]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jitc-2020-001636"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001636","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}